Elmira M. Zulkarneeva

Elmira M. Zulkarneeva

Auto-generated profile, based on publicly available information

Elmira M. Zulkarneeva

Russian Journal of Woman and Child Health, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Russian Journal of Woman and Child Health
Verified
Journal Article
Open access
VRV.E. Radzinskiy
V.E. Radzinskiy
IMI.B. Manukhin
I.B. Manukhin
IOI.M. Ordiyants
I.M. Ordiyants
VBV.E. Balan
V.E. Balan
ETE.V. Tikhomirova
E.V. Tikhomirova
EZE.M. Zulkarneeva
E.M. Zulkarneeva

14 July 2023 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
LZLiana Z. Ziganshina
Liana Z. Ziganshina
SMSofia Yurevna Muslimova
Sofia Yurevna Muslimova
ISIndira V. Sakhautdinova
Indira V. Sakhautdinova
EZElmira M. Zulkarneeva
Elmira M. Zulkarneeva
ISIndita V. Sahautdiniva
Indita V. Sahautdiniva
Hypoestrogenism associated with menopause has a strong negative effect on the condition of the vagina and urinary tract, and often leads to the development of genitourinary menopausal syndrome, significantly disrupting the quality of life of women. Menopausal vulvovaginal atrophy is diagnosed in 36 to 90% of peri- and postmenopausal women. In recent years, it has been revealed that this condition is also present in 19% of women aged 4045 years during premenopause. Aim. The aim of the study was to study the relationship between the dynamics of the severity of symptoms and their impact on the quality of life of women, and the clinical manifestations of postmenopausal atrophic vaginitis, depending on the stage of postmenopause. Results. Patients in the early postmenopausal period had a vaginal health index consistent with moderate atrophy. Throughout the postmenopausal period studied, clinical manifestations of vaginal atrophy progressed, and in the late menopausal period, the vaginal health index was consistent with severe atrophy. Conclusion. In our opinion the therapy of vulvovaginal atrophy should begin with the period of early menopause. At this time, women are most interested in treatment, as their quality of life suffers significantly due to the newly appeared extremely unpleasant sensations. At the same time, minor atrophic changes in the tissues of the vagina and vulva are easier to treat.

1 January 2023 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
MEMoscow Russian Medical Academy Of Continuous Professional Education
Moscow Russian Medical Academy Of Continuous Professional Education
NPN.M. Podzolkova
N.M. Podzolkova
MSM.Yu. Skvortsova
M.Yu. Skvortsova
NSN.V. Spiridonova
N.V. Spiridonova
VGV.A. Guryeva
V.A. Guryeva
SSS.B. S.B.Nazarov
S.B. S.B.Nazarov
Objective. To evaluate the efficacy and safety of micronized progesterone as part of the most common treatment regimens for preventing miscarriage, as well as patient satisfaction and adherence; to examine the overall clinical response to therapy and to determine the rate of pregnancy prolongation until fetal viability is reached based on physician assessments. Patients and methods. Data were collected from a sample of 300 patients in their first trimester of pregnancy who were admitted to hospital for inpatient treatment (with bleeding and/or pain) and to whom as part of pharmacotherapy regimens Prajisan® was prescribed at a daily dose of 400 mg (200 mg twice daily, intravaginal route; as indicated and according to instructions for medical use). All the procedures performed were routine, which defined the non-interventional nature of this study. Patient medical records and characteristics of their current pregnancy, including the use of medications, the presence of complications, length of stay, and adverse events that occurred during the entire period of observation and treatment, were assessed. Moreover, the survey contained additional, specially designed questionnaires to assess the patient’s condition in dynamics, the physician’s satisfaction with the therapeutic effect, and the patient’s satisfaction with the treatment used (Likert scale). The primary endpoint was the prolongation of pregnancy until hospital discharge; the secondary endpoint was the prolongation of pregnancy until potential fetal viability (up to 22 weeks and 0 days). Mathematical and statistical data processing was performed using standard software packages Statistica (v7.0) and SPSS Statistics (v23.0). Results. The efficacy of combination therapy (achievement of the primary endpoint), which included micronized progesterone (Prajisan® 200 mg intravaginally twice daily), was 96.84%. The therapy was not associated with adverse events in 100% of cases. Physician and patient satisfaction with the convenience of use (according to the mean Likert score) did not differ significantly and was 4.21 ± 0.7 and 4.07 ± 0.8, respectively. Physician satisfaction with the clinical response to treatment was significantly higher than patient satisfaction with the convenience of use (mean Likert score was 4.39 ± 0.5 and 4.07 ± 0.8, respectively). The secondary endpoint was reached in 100% of the patients discharged from hospital with progression of pregnancy. No adverse events were recorded. Conclusion. The findings of this prospective multicenter study obtained in different medical institutions in nine major cities of Russia (including megacities) allow us to conclude about the positive experience with the use of Prajisan® and to recommend it for pregnancy prolongation in the routine practice of Russian obstetricians and gynecologists. Key words: early pregnancy loss, miscarriage, risk factors, prevention, micronized progesterone